by | Jul 9, 2024 | Publications
J Transl Med. 2024 Jul 8;22(1):638. doi: 10.1186/s12967-024-05452-9. NO ABSTRACT PMID:38977990 | DOI:10.1186/s12967-024-05452-9
by | Jul 8, 2024 | Publications
Blood Lymphat Cancer. 2024 Jul 2;14:49-62. doi: 10.2147/BLCTT.S468836. eCollection 2024. ABSTRACT BACKGROUND: The albumin-to-globulin ratio (AGR) and neutrophil-to-lymphocyte ratio (NLR) have been recently regarded as promising prognostic factors in various...
by | Jul 8, 2024 | Publications
Hemasphere. 2024 Jul 4;8(7):e81. doi: 10.1002/hem3.81. eCollection 2024 Jul. ABSTRACT Recommendations regarding the best time to start treatment in patients with relapsed/refractory multiple myeloma (RRMM) after biological relapse/progression (BR) are unclear. This...
by | Jul 8, 2024 | Publications
Blood Coagul Fibrinolysis. 2024 Jul 1;35(5):293-295. doi: 10.1097/MBC.0000000000001311. Epub 2024 May 23. ABSTRACT This case involves a 58-year-old patient, with no personal or family history of bleeding, diagnosed with stage III-A IgG Kappa multiple myeloma in 2016...
by | Jul 8, 2024 | Publications
Clin Lymphoma Myeloma Leuk. 2023 Sep;23 Suppl 2:S248. doi: 10.1016/S2152-2650(23)01995-X. Epub 2023 Sep 26. ABSTRACT This article has been retracted: please see Elsevier Policy on Article Withdrawal (https://www.elsevier.com/locate/withdrawalpolicy). This article has...
by | Jul 7, 2024 | Publications
Transplant Cell Ther. 2024 Jul 4:S2666-6367(24)00490-1. doi: 10.1016/j.jtct.2024.06.030. Online ahead of print. ABSTRACT BACKGROUND: In patients with multiple myeloma, the presence of high-risk cytogenetic abnormalities is associated with worse disease control and...
